Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,045
datasets available to search
ShareScore release 0.9.0
Dataset results
1,045 results for “neoadjuvant chemotherapy”
GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
GEO Series GSE32646. Homo sapiens. 115 samples. Type: Expression profiling by array.
A stroma-related gene signature predicts sensitivity to epirubicin-containing neoadjuvant chemotherapy in breast cancer.
GEO Series GSE4779. Homo sapiens. 102 samples. Type: Expression profiling by array.
Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer
GEO Series GSE206339. Homo sapiens. 128 samples. Type: Other.
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast
GEO Series GSE66399. Homo sapiens. 156 samples. Type: Expression profiling by array; Genome variation profiling by SNP array.
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
GEO Series GSE124305. Homo sapiens. 133 samples. Type: Expression profiling by array.
Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [scRNA-seq]
GEO Series GSE303696. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Characterization of residual cancer by comparison of a pair of organoids established from a patient with ESCC before and after neoadjuvant chemotherapy (xenografts)
GEO Series GSE243146. Homo sapiens. 6 samples. Type: Expression profiling by array.
A Single-Cell Atlas of HR+ Breast Cancer Reveals the Shifting of the Tumor Microenvironment in Response to Neoadjuvant Chemotherapy
GEO Series GSE205472. Homo sapiens. 13 samples. Type: Expression profiling by high throughput sequencing.
Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [MON_RNAseq]
GEO Series GSE302946. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Characterization of residual cancer by comparison of a pair of organoids established from a patient with ESCC before and after neoadjuvant chemotherapy (in vitro)
GEO Series GSE243145. Homo sapiens. 2 samples. Type: Expression profiling by array.
Dataset related to article "PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy."
<p>PURPOSE:</p> <p>To assess the role of radiomics parameters in predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer.</p> <p>METHODS:</p> <p>Seventy-nine patients who had undergone pretreatment staging <sup>18</sup>F-FDG PET/CT and treatment with NAC between January 2010 and January 2018 were included in the study. Primary lesions on PET images were delineated, and extraction of first-, second-, and higher-order imaging features was performed using LIFEx software. The relationship between these parameters and pCR to NAC was analyzed by multiple logistic regression models.</p> <p>RESULTS:</p> <p>Nineteen patients (24%) had pCR to NAC. Different models were generated on complete information and imputed datasets, using univariable and multivariable logistic regression and least absolute shrinkage and selection operator (lasso) regression. All models could predict pCR to NAC, with area under the curve values ranging from 0.70 to 0.73. All models agreed that tumor molecular subtype is the primary predictor of the primary endpoint.</p> <p>CONCLUSIONS:</p> <p>Our models predicted that patients with subtype 2 and subtype 3 (HER2+ and triple negative, respectively) are more likely to have a pCR to NAC than those with subtype 1 (luminal). The association between PET imaging features and pCR suggested that PET imaging features could be considered as potential predictors of pCR in locally advanced breast cancer patients.</p>
Dataset related to article "Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy."
<p>INTRODUCTION:</p> <p>The purpose of this study was to assess the predictive and prognostic role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in candidates with stage III non-small-cell lung cancer (NSCLC) to neoadjuvant chemotherapy.</p> <p>PATIENTS AND METHODS:</p> <p>Sixty-six patients with stage III NSCLC treated with induction chemotherapy from March 2013 to December 2017 were retrospectively identified. Response assessment were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and European Organisation for Research and Treatment of Cancer (EORTC) criteria. 18F-FDG PET/CT metabolic parameters were analyzed as absolute values as well as percentage changes (Δ) between 2 consecutive scans, for primary tumor (T) and for regional lymph nodes (N). All clinical variables and metabolic parameters were compared with treatment response and correlated with progression-free survival (PFS) and overall survival (OS), based on a median follow-up of 9.4 months.</p> <p>RESULTS:</p> <p>Post-induction therapy standardized uptake value (SUV)max_T, SUVmean_T, metabolic tumor volume (MTV_T), and total lesion glycolysis of the tumor (TLG_T) varied significantly between responders and non-responders (6.6 vs. 13.8; P = .001; 4.2 vs. 8.1; P < .001; 6 vs. 17.9; P = .002; and 24.1 vs. 136.3; P < .001, respectively). Likewise, percentage changes (Δ_T) were significantly different between the 2 groups (P < .001). Along with primary tumor, also post-SUVmax_N, post-SUVmean_N, and post-TLG_N (P = .024, P = .015, and P = .024, respectively), as well as all percentage changes (Δ_N) were different between responders and non-responders. RECIST 1.1 and EORTC response classifications were discordant in 27 patients (40.9%; κ = 0.265; P = .003). On multivariate analysis, post-TLG_N was an independent predictor for both PFS and OS, whereas RECIST 1.1 was a predictor only for OS.</p> <p>CONCLUSIONS:</p> <p>Several metabolic parameters may differentiate responders from non-responders following neoadjuvant chemotherapy in stage III NSCLC. As compared with RECIST 1.1, EORTC seems to be more appropriate for evaluation therapeutic response. Finally, post-TLG_N has significant prognostic information.</p>
Dataset related to article: Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
<p>Systemic inflammation is associated with increased aggressiveness of breast cancer and can contribute to decreased activity of neoadjuvant treatments. Biomarkers of systemic inflammation are easily obtained from routine blood count and are highly cost-effective, having great potential to steer cancer prognosis in clinical practice. In our study we tested the hypothesis that high values of these biomarkers might have an effect on clinical outcomes in a population of patients treated with neoadjuvant chemotherapy for breast cancer. Results of our study, together with data from the literature, hint at a possible role of inflammatory markers in the diagnostic and therapeutic algorithm of breast cancer, where specific pre-operative blood cell ratios could be used in combination with biological and clinical factors to tailor adjuvant therapy.</p>
Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT01216124. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Transcriptome sequencing reveals expression characteristics of osteosarcoma before and after neoadjuvant chemotherapy
GEO Series GSE218037. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.
Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy
GEO Series GSE302947. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Targeting CDK4/6 epigenetically impairs DNA damage repair to overcome the resistance to neoadjuvant chemotherapy in locally advanced rectal cancer II
GEO Series GSE207521. Homo sapiens. 13 samples. Type: Expression profiling by high throughput sequencing.
TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy
GEO Series GSE190275. Homo sapiens. 60 samples. Type: Expression profiling by array.
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
GEO Series GSE235067. Homo sapiens. 84 samples. Type: Expression profiling by array.
Response prediction to neoadjuvant chemotherapy
GEO Series GSE29561. Homo sapiens. 22 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.